Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares after option exercise
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Monte Rosa Therapeutics Chief Scientific Officer Sharon Townson reported an exercise-and-sell transaction in company stock. On July 6, 2026, she exercised options to acquire 6,000 shares of common stock at $6.14 per share and sold a total of 6,000 shares in open-market trades, including 400 shares at $24.13 and additional shares at a weighted average price of $23.2495 within a range of $22.97 to $23.65. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After the trades, she directly holds 67,845 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 6,000 shares ($139,849)
Net Sell
4 txns
Insider
Townson Sharon
Role
Chief Scientific Officer
Sold
6,000 shs ($140K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 6,000 | $0.00 | -- |
| Exercise | Common Stock | 6,000 | $6.14 | $37K |
| Sale | Common Stock | 5,600 | $23.2495 | $130K |
| Sale | Common Stock | 400 | $24.13 | $10K |
Holdings After Transaction:
Stock Option (Right to Buy) — 197,290 shares (Direct, null);
Common Stock — 73,845 shares (Direct, null)
Footnotes (1)
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.97 to $23.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The shares underlying this option are fully vested and exercisable.
Key Figures
Shares sold: 6,000 shares
Sale price (block 1): $24.13 per share
Sale price (block 2 avg.): $23.2495 per share
+3 more
6 metrics
Shares sold
6,000 shares
Total common stock sold on July 6, 2026
Sale price (block 1)
$24.13 per share
400-share open-market sale
Sale price (block 2 avg.)
$23.2495 per share
Weighted average for additional sales, range $22.97–$23.65
Options exercised
6,000 shares
Common stock acquired via option exercise
Option exercise price
$6.14 per share
Strike price for stock option exercised
Shares held after
67,845 shares
Direct common stock ownership following transactions
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), Exercise or conversion of derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What did Monte Rosa Therapeutics (GLUE) CSO Sharon Townson do in this Form 4?
Sharon Townson reported exercising options for 6,000 Monte Rosa Therapeutics shares and selling 6,000 shares in open-market transactions. The activity reflects an exercise-and-sell pattern disclosed in a regulatory filing.
At what price did Sharon Townson exercise options for Monte Rosa Therapeutics (GLUE) stock?
She exercised stock options to acquire 6,000 Monte Rosa Therapeutics common shares at $6.14 per share. This option exercise converted derivative rights into actual shares before subsequent open-market sales on the same date.
Were Sharon Townson’s Monte Rosa Therapeutics (GLUE) trades under a Rule 10b5-1 plan?
Yes, the filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on February 27, 2026. Such plans pre-schedule trades, indicating the timing was established in advance.
What type of insider transactions are reported for Monte Rosa Therapeutics (GLUE) in this Form 4?
The Form 4 reports an option exercise and open-market sales of common stock. One transaction reflects exercising a stock option, while two separate entries show sales of the resulting shares at market prices.